{"article_title": "Teva in talks to buy Allergan\u2019s generics unit", "article_keywords": ["mylan", "buy", "deal", "seeking", "industry", "allergans", "teva", "market", "generics", "healthcare", "talks", "allergan", "maker", "unit", "latest"], "article_url": "http://www.marketwatch.com/story/teva-in-talks-to-buy-allergans-generics-unit-2015-07-26", "article_text": "Israeli drug maker Teva Pharmaceutical Industries Ltd. is in talks to combine with Allergan PLC\u2019s big generic-drug business, in a move that would further consolidation in the health-care industry and likely mean the end of Teva\u2019s pursuit of another acquisition.\n\nA deal for the Allergan business, valued at about $45 billion, could be announced as early as Monday, according to people familiar with the matter. The Allergan AGN, -0.45% unit would be spun off and combined with Teva\u2014already the world\u2019s biggest seller of generic medicines with a market value of $60 billion\u2014one of the people said.\n\nTeva TEVA, -0.40% has been seeking to buy Mylan NV, MYL, +0.57% a deal Mylan has been resisting as it pursues fellow drug maker Perrigo Co. PLC PRGO, +0.32%\n\nThe merger would be the latest to shake up a major sector of the health-care industry, and come on the heels of two big announcements in which four of the largest managed-care companies\u2014Anthem Inc. ANTM, +1.93% and Cigna Corp. CI, +3.60% and Aetna Inc. AET, +1.85% and Humana Inc. HUM, +2.30% \u2014agreed to combine into two companies, in deals worth a combined $82 billion.\n\nCompanies of all stripes are scrambling for tie-ups following the Supreme Court\u2019s decision last month that upheld the 2010 Affordable Care Act health-care overhaul. Teva and Allergan, one of the most active acquires in any industry in recent years, would be the latest example of companies consolidating in part to achieve the health savings sought by policy makers.\n\nFor Teva, a deal with Allergan would largely give the company what it has been seeking from a Mylan deal: increased scale in the hotly competitive generic-drug market, and an opportunity to pursue further cost reductions that could help it cope with razor-thin margins on the low-price medicines.\n\nAn expanded version of this report appears on WSJ.com\n\nMore from MarketWatch", "article_metadata": {"lifp_basePath": "https://id.marketwatch.com/access", "twitter": {"domain": "marketwatch.com", "image": {"width": 569, "identifier": "http://s.marketwatch.com/public/resources/MWimages/MW-CT250_pills__MG_20140902105852.jpg", "height": 398}, "description": "Israeli drug maker Teva Pharmaceutical Industries Ltd. is in talks to combine with Allergan PLC\u2019s big generic-drug business, in a move that would further consolidation in the health-care industry and likely mean the end of Teva\u2019s pursuit of another acquisition.", "card": "summary_large_image", "site": {"id": 624413}}, "parsely-author": "Liz Hoffman", "article.content_group": "marketwatch", "article.section": "Industries", "parsely-type": "post", "description": "Israeli drug maker Teva Pharmaceutical Industries Ltd. is in talks to combine with Allergan PLC\u2019s big generic-drug business, in a move that would further consolidation in the health-care industry and likely mean the end of Teva\u2019s pursuit of another acquisition.", "parsely-link": "http://www.marketwatch.com/story/teva-in-talks-to-buy-allergans-generics-unit-2015-07-26", "author": "Dana Mattioli, Jonathan D. Rockoff, Dana Cimilluca , Liz Hoffman", "parsely-title": "Teva in talks to buy Allergan\u2019s generics unit", "apple-itunes-app": "app-id=336693422", "parsely-pub-date": "2015-07-26T12:29:00-04:00", "page.site": "marketwatch", "robots": "noarchive,noodp", "fb": {"app_id": 283204329838}, "parsely-section": "MW_Industries", "article": {"publisher": "https://www.facebook.com/marketwatch"}, "viewport": "width=device-width, initial-scale=1, maximum-scale=1", "og": {"site_name": "MarketWatch", "description": "Israeli drug maker Teva Pharmaceutical Industries Ltd. is in talks to combine with Allergan PLC\u2019s big generic-drug business, in a move that would further consolidation in the health-care industry and likely mean the end of Teva\u2019s pursuit of another acquisition.", "title": "Teva in talks to buy Allergan\u2019s generics unit", "url": "http://www.marketwatch.com/story/teva-in-talks-to-buy-allergans-generics-unit-2015-07-26", "image": "http://s.marketwatch.com/public/resources/MWimages/MW-CT250_pills__MG_20140902105852.jpg", "type": "article"}, "ob": {"image": "http://s.marketwatch.com/public/resources/MWimages/MW-CT250_pills__MG_20140902105852.jpg"}, "article.id": "5F60C402-33A0-11E5-878A-FEC591F7CD8E", "position": 1}, "_id": "\"57477af36914bd0286fcbc2e\"", "article_summary": "Israeli drug maker Teva Pharmaceutical Industries Ltd. is in talks to combine with Allergan PLC\u2019s big generic-drug business, in a move that would further consolidation in the health-care industry and likely mean the end of Teva\u2019s pursuit of another acquisition.\nA deal for the Allergan business, valued at about $45 billion, could be announced as early as Monday, according to people familiar with the matter.\nCompanies of all stripes are scrambling for tie-ups following the Supreme Court\u2019s decision last month that upheld the 2010 Affordable Care Act health-care overhaul.\nThe Allergan AGN, -0.45% unit would be spun off and combined with Teva\u2014already the world\u2019s biggest seller of generic medicines with a market value of $60 billion\u2014one of the people said.\nTeva and Allergan, one of the most active acquires in any industry in recent years, would be the latest example of companies consolidating in part to achieve the health savings sought by policy makers."}